Biologic therapies such as mepolizumab and benralizumab are currently utilised in the treatment of eosinophilic asthma, and are emerging in the management of eosinophilic chronic rhinosinusitis (eCRS). These biologics inhibit the interaction of IL-5 with its receptor, thus impairing cytokine signalling and eosinophil inflammation. Mepolizumab does so by targeting IL-5, whereas benralizumab targets the α chain of the IL-5 receptor. This study compares the sinonasal tissue response to anti-IL-5 biologic therapies in patients with eCRS.
Methods
A cross-sectional study of adult eCRS patients who had completed at least 2 cycles of biologic therapy and underwent endoscopic sinus surgery as part of their management were included. Sinonasal mucosal tissue biopsies were obtained intraoperatively and assessed with structured histopathological examination. Comparisons of tissue histopathology outcomes following treatment with mepolizumab or benralizumab were performed.
Results
18 patients (age 49.6 ± 14.2 years, 47% female, 100% co-morbid asthma) were included in this study, comprising 10 patients managed with mepolizumab and 8 patients managed with benralizumab. Even after mepolizumab, the tissue had predominantly eosinophilic inflammation compared to benralizumab (90% v 0%, p < 0.01), which demonstrated a greater lymphoplasmacytic inflammation (10% v 75%, χ2(2) = 14.53, p < 0.01). Compared with benralizumab, mepolizumab had increased tissue eosinophil count (100% v 37.5% >10 eosinophils/HPF, τb = −8.47, p < 0.001) and more severe subepithelial oedema (80% v 37.5% severe, τb = −2.37, p = 0.02).
Conclusion
Tissue histopathologic outcomes reflect the differing mechanism of action of mepolizumab and benralizumab in eCRS. Further analysis at the tissue level will provide further information to guide application of mAbs in type 2 inflammatory diseases.
SmithKAPulsipherAGabrielsenDAAltJA.Biologics in chronic rhinosinusitis: an update and thoughts for future directions.Am J Rhinol Allergy. 2018;
32(5):412–423.
2.
FokkensWJLundVBachertC, et al.
EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;
74(12):2312–2319.
3.
ShahSAIshinagaHTakeuchiK.Pathogenesis of eosinophilic chronic rhinosinusitis.J Inflamm. 2016;
13(1):11.
4.
PelaiaCVatrellaABuscetiMT, et al.
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.Drug Des Devel Ther. 2017;
11:3137–3144.
5.
EmmaRMorjariaJBFuochiVPolosaRCarusoM.Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.Ther Adv Respir Dis. 2018;
12: 1753466618808490–1753466618808490.
6.
MenzellaFLusuardiMMontanariGGaleoneCFacciolongoNZucchiL.Clinical usefulness of mepolizumab in severe eosinophilic asthma. Ther Clin Risk Manag. 2016;
12:907–916.
7.
CavaliereCFratiFRidoloE, et al.
The spectrum of therapeutic activity of mepolizumab. Expert Rev Clin Immunol. 2019;
15(9):959–967.
8.
GhaziATrikhaACalhounWJ.Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma. Expert Opin Biol Therapy. 2012;
12(1):113–118.
9.
PelaiaCCalabreseCVatrellaA, et al.
Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma.Biomed Res Int. 2018;
2018:4839230–4839230.
10.
ArronJRChoyDFScheerensHMatthewsJG.Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.Ann Am Thorac Soc. 2013;
10(Suppl):S206–S213.
11.
TiotiuA.Biomarkers in asthma: state of the art. Asthma Res Pract. 2018;
4:10–10.
12.
RenLZhangNZhangLBachertC.Biologics for the treatment of chronic rhinosinusitis with nasal polyps – state of the art.World Allergy Org J. 2019;
12(8):100050.
13.
MasperoJHarrisonTWerkströmVWuYGopalanGZangrilliJ.Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIROCCO and CALIMA trials. J Allergy Clin Immunol. 2018;
141(2):AB12.
14.
BleeckerERFitzGeraldJMChanezP, et al.
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting B2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.Lancet. 2016;
388(10056):2115–2127.
15.
FitzGeraldJMBleeckerERNairP, et al.
Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;
388(10056):2128–2141.
16.
LiWHoJGraysonJW, et al.
Evaluation of diffuse type 2 dominant or eosinophilic chronic rhinosinusitis with corticosteroid irrigation after surgical neosinus cavity formation.JAMA Otolaryngol Head Neck Surg. 2021;
147(4):360–367.
17.
SridharSLiuHPhamT-HDameraGNewboldP.Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019;
20(1):14.
18.
RoufosseF.Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma.Front Med. 2018;
5:49.
19.
WalterSHoJAlvaradoR, et al.
Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: a systematic review. Clin Exp Allergy. 2020; 50(11):1212–1222.
20.
McHughTSnidvongsKXieMBanglawalaSSommerD.High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis.Int Forum Allergy Rhinol. 2018;
8(12):1421–1429.
21.
BarhamHPOsbornJLSnidvongsKMradNSacksRHarveyRJ.Remodeling changes of the upper airway with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2015;
5(7):565–572.
22.
SnidvongsKLamMSacksR, et al.
Structured histopathology profiling of chronic rhinosinusitis in routine practice. Int Forum Allergy Rhinol. 2012;
2(5):376–385.
23.
PonikauJUSherrisDAKephartGM, et al.
Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to asthma?J Allergy Clin Immunol. 2003;
112(5):877–882.
24.
JiangNKernRCAltmanKW.Histopathological evaluation of chronic rhinosinusitis: a critical review.Am J Rhinol Allergy. 2013;
27(5):396–402.
25.
HoJLiWGraysonJW, et al.
Systemic medication requirement in post-surgical patients with eosinophilic chronic rhinosinusitis.Rhinology. 2021;
59(1):59–65.
26.
Flood-PagePTMenzies-GowANKayABRobinsonDS.Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.Am J Respir Crit Care Med. 2003;
167(2):199–204.
27.
Menzies-GowAFlood-PagePSehmiR, et al.
Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.J Allergy Clin Immunol. 2003;
111(4):714–719.
28.
KellyEAEsnaultSLiuLY, et al.
Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma.Am J Respir Crit Care Med. 2017;
196(11):1385–1395.
29.
HaldarPBrightlingCEHargadonB, et al.
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;
360(10):973–984.
30.
Montero-PérezOContreras-ReyMBSánchez-GómezE.Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice.Drugs Context. 2019;
8:212584–212584.
31.
OrtegaHGLiuMCPavordID, et al.
Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;
371(13):1198–1207.
32.
MukherjeeMForeroDFTranS, et al.
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Eur Respir J. 2020;
56(4):2000117.
33.
LavioletteMGossageDLGauvreauG, et al.
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.J Allergy Clin Immunol. 2013;
132(5):1086.e1085–1096.e1085.
34.
BhallaAZhaoNRivasDD, et al.
Exacerbations of severe asthma while on anti-IL-5 biologics.J Investig Allergol Clin Immunol. 2020;
30(5):307–316.
35.
NairPWenzelSRabeKF, et al.
Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;
376(25):2448–2458.
36.
BelEHWenzelSEThompsonPJ, et al.
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.N Engl J Med. 2014;
371(13):1189–1197.
37.
PoznanskiSMMukherjeeMZhaoN, et al. Asthma exacerbations on benralizumab are largely non-eosinophilic. Allergy. 2021;76(1):375–379.
38.
Sabogal Piñeros YS, Bal SM, van de Pol MA et al.
Anti–IL-5 in mild asthma alters rhinovirus-induced macrophage, B-cell, and neutrophil responses (MATERIAL). A placebo-controlled, double-blind study. Am J Respir Crit Care Med. 2019;
199(4):508–517.
39.
MotekiHYasuoMHamanoHUeharaTUsamiS-i.IgG4-related chronic rhinosinusitis: a new clinical entity of nasal disease.Acta Oto-Laryngologica. 2011;
131(5):518–526.
40.
OhnoKKimuraYMatsudaY, et al.
Increased number of IgG4-positive plasma cells in chronic rhinosinusitis.Acta Oto-Laryngologica. 2017;
137(2):186–190.
41.
KoyamaTKariyaSSatoY, et al.
Significance of IgG4-positive cells in severe eosinophilic chronic rhinosinusitis.Allergol Int. 2019;
68(2):216–224.
42.
RamezanpourMHuHLauA, et al.
Increased serum IgG4 associates with asthma and tissue eosinophilia in chronic rhinosinusitis patients. Pathogens. 2020;
9(10):828.
43.
DobererDTrejo BittarHEWenzelSE.Should lung biopsies be performed in patients with severe asthma?Eur Respir Rev. 2015;
24(137):525–539.
44.
WenzelSEVitariCAShendeMStrolloDCLarkinAYousemSA.Asthmatic granulomatosis. Am J Respir Crit Care Med. 2012;
186(6):501–507.
45.
MoranAMRamakrishnanSBorgCA, et al.
Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma.Am J Respir Crit Care Med. 2020;
202(9):1314–1316.
46.
PavordIDKornSHowarthP, et al.
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;
380(9842):651–659.
